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Abstract
Introduction:  Donor  sites  of  split-thickness  skin  grafts  (STSGs)  are painful  and  limit  patient
rehabilitation.  We  conducted  this  study  to  assess  the  efficacy  of  a  non-adherent  polyurethane
dressing  in reducing  pain  and  its  effect on  the  epithelialization  rate  of  donor  sites  of  STSGs.
Methods: Fifteen  patients  requiring  an  STSG  were  included.  In  10  patients  the  donor  sites  were
randomly divided  into  two  halves  and covered  with  either  a  non-adherent  polyurethane  dress-
ing or a  standard  non-adherent  gauze.  In  five  patients  with  bilateral  donor  sites,  one  side  was
covered with  the  non-adherent  polyurethane  dressing  and  the  other  with  non-adherent  gauze.
The pain  was  assessed  with  a  visual  analog  scale  and  epithelialization  was  also  assessed,  calcu-
lating non-epithelialized  areas  with  image  software  by  a  blinded  surgeon.  Epithelialization  of
the wounds  covered  with  the  non-adherent  polyurethane  dressing  was  assessed  at  day  8  and 10
and those  with  non-adherent  gauze  at  day  10.
Results: Postoperative  pain  significantly  decreased  with  the  non-adherent  polyurethane  dress-
ing during  the  length  of  the  study  (6.07  ±  1.46  vs.  1.72  ± 1.6)  and  at  each  time  point  (p  < 0.001).
Epithelialization  was  not  affected  with  the polyurethane  dressing,  compared  to  the standard
method.
Conclusions:  Non-adherent  polyurethane  dressing  achieves  a  significant  reduction  of  pain  in the
skin-grafted donor  sites  without  affecting  epithelialization.
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Introduction
Split  thickness  skin  grafts  (STSGs)  are routinely  used  to
cover  a  variety  of  wounds  caused  by  burns,  trauma or  tumor
excisions,  etc.  Due  to  their  reliability  and  the relatively
high  availability  of  donor  sites,  STSGs  represent  one  of  the
first  options  in reconstruction.1--3 However,  harvesting  STSGs
invariably  produces  a new  open  wound  in the donor  site,
which  can be  painful  and requires  fast and  effective  re-
epithelialization.
Typically,  the donor  site  is  covered  with  non-adherent
fine-meshed  gauze  impregnated  with  different  ointments.4,5
Unfortunately,  this  technique  is  usually  painful  and  is  one  of
its  main  drawbacks.6 In fact,  pain  related  to  donor  sites  is
the  most  important  patient  complaint  within  the first  ten
days  after  graft  harvest.7 This  is  particularly  important  in
those  cases  where  prompt  rehabilitation  is  required,  e.g.,
severely  burned  patients.
Recent  technological  advances  have  made  the creation
of  new  dressings  designed  to  cause  less  discomfort  in  donor
site  wounds  possible.8,9 As  newer options  are  seen  on  an
almost  daily  basis,  the current  trend  in donor-site  manage-
ment  is  oriented  to  reduce  pain  as well  as  promote  rapid
and  effective  re-epithelialization.10,11
Among  the dressings  that  have  been  used  in  donor  site
wounds  are  hydrocolloids  (Duoderm®) that  typically  forms
a  scab  over  the wound  and  an exudate  with  an  unpleas-
ant  odor  macerating  the surrounding  skin,  and Biobrane®,
a  biocomposite  porcine  type  I  collagen  attached  to a flexi-
ble  synthetic  membrane  that  has  been  effective  in  reducing
pain.12 One  of  the main  issues  with  Biobrane® is that  fluid
accumulates  underneath  if  not properly  used,  making  the
area  prone  to  infection.12
Mepilex® (Mölnlycke  Health  Care,  US,  LLC,  Norcross,
GA)  is  a  non-adherent  polyurethane  dressing  consisting  of
a  polyurethane  absorbing  sponge,  adaptable  with  Safetac
Technology®.  According  to  the manufacturers,  this  technol-
ogy  permits  the  dressing  to  adhere  to  the  surrounding  skin,
but  not  to  the  moist  wound  bed,  potentially  reducing  pain,
preventing  maceration  and minimizing  the  drag  of epithe-
lial  cells  at  removal.13,14 Furthermore,  it seals  the wound  to
prevent  leakage  of  exudate  and isolates  the  wound  from  the
environment,  minimizing  skin  infections.14
Due  to  these  characteristics,  it is  potentially  beneficial
for  STSGs.  We  conducted  a  prospective  and  randomized
study  to assess  the efficacy  of  Mepilex® in  reducing  pain  of
STSG  donor  sites  and  on epithelialization  compared  with  our
traditional  management  (non-adherent  dressing).
Patients and methods
We  conducted  a  prospective,  comparative  and  randomized
clinical  trial  between  January  and  August,  2012.  The  Ethics
Committee  of our  hospital  approved  the study  protocol.  All
patients  enrolled  in the study  signed  an informed  consent.
Inclusion  criteria  included  patients  requiring  split-thickness
skin  grafts  secondary  to  any  etiology.  The  patients  were
assigned  to two  groups.  The  first  group  included  ten patients
with  a  donor  site of  at  least  20  cm  ×  10  cm  on  one  thigh.
The  second  group  included  five  patients  who  required  bilat-
eral  harvest  of  STSGs  of  at  least  10  cm  ×  10  cm  on  each
Figure  1  Donor  site  assessment:  (a)  control  area  covered  with
non  adherent  gauze,  (b)  Mepilex®-covered  area.
thigh.  Exclusion  criteria  included  pregnant  women,  immuno-
suppressed  patients,  a known allergy  to  any  component  of
the  dressings,  dermatological  diseases,  and  anticoagulant  or
corticosteroid  treatment.
Donor  site  management
All  skin  grafts  were  harvested  from  the proximal-
anterolateral  thigh  by  the  same  surgeon.  The  grafts  were
harvested  with  a dermatome  to  produce  a homogeneous
thickness  of  0.4  mm.  In  patients  with  a unilateral  donor
site,  the wound  was divided  into  proximal  and  distal  halves
and  randomly  assigned  to  be covered  with  either  a  non-
adherent  dressing  (Adaptic®,  Johnson  & Johnson,  Inc.,  New
Brunswick,  NJ),  our  standard method,  or  Mepilex®.  The  area
covered  with  non-adherent  gauze  was  managed  in  a semi-
open  fashion,  with  no  secondary  dressing.  The  Mepilex®
patch  was  secured  with  an adhesive  bandage  (Hypafix®, BSN
medical,  Inc., Charlotte,  NC) and  left on  site  until  the 8th
day  (Fig.  1).  In the  patients  with  bilateral  donor  sites,  one
side  was  covered  with  Mepilex® and  the  other  with  Adaptic®
Figure  2  Patient  with  bilateral  donor  site:  one  side  was  cov-
ered with  Mepilex  (right)  and  the  contralateral  side  (left)  with
non-adherent  gauze.
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Figure  3  Donor  site  assessment:  (a)  donor  site  area  to  be  assessed.  The  surgeon  assessing  the  epithelialization  rate  was  blinded
to group  and  time  point  of  the  area;  (b)  extension  (in  pixels)  of  the  non-healed  area  was  determined  by  diviiding  the  unhealed  area
over the  total  donor  site  area.
as  previously  described  (Fig.  2).  This  assignment  was  ran-
domly  made.
Pain
Pain  of  donor  sites  was  assessed  with  a visual  analog  scale
(VAS)  using  a  scale  from  0  to  10  on  days  3, 5,  7  and  9  after
grafting.
Assessment  of  epithelialization
Epithelialization  was  assessed  on  the  8th  and  10th  days
in  the  Mepilex®-covered  areas  and  on  the 10th day  in  the
areas covered  with  non-adherent  gauze.  To  remove  the
Adaptic  gauze,  a thick layer  of  petrolatum  was  applied
over  the  area on  the 9th  day  and  left overnight.  The  next
morning  the  adaptic  gauze  was  removed  at  the  patient’s
bedside.  This  procedure  was  painless  and  no  analgesic  was
required.
Mepilex® was  removed  on  the  8th  day  at  the patient’s
bedside.  If the  Mepilex®-covered  area was  not fully  healed
by  the 8th  day,  it was  covered  again,  as  previously  explained
for  the Mepilex®-covered  areas.  Photographs  were  taken  of
both  areas  with  a  digital  camera  (Fuji  Finepix  S,  Super  EBC
Fujinon  lens:  26×  Optical  zoom  f = 4.3--111.8,  1:3.1--5.9)
using  standardized  photo  settings  (30 cm  distance,  f30,  1/30
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and  ISO  100)  under  standard  daylight  fluorescent  lamps  (GE
T8  Standard  linear  fluorescent  lamp  36  W, 2750  lm).
The  photographs  were  assessed  by  a  plastic  surgeon
blinded  to  the  group  and  to  the  time  point  after grafting.
Epithelialization  percentage  was  calculated  by  analyzing  the
photographs  of  the donor  sites  using  image  software  (Adobe
Photoshop®).  Briefly,  the donor  site  area  was  selected  and
the  amount  of  pixels  within  the selection  was  determined.
Then,  the  unhealed  areas  were  selected  and  the  respec-
tive  size  of this  selection  was  determined.  The  percentage
of  epithelialization  was  calculated  by dividing the non-
epithelialized  area  by  the total  donor  site surface  area
(Fig.  3a  and  b).
Statistical  analysis
Difference  in scores  of the visual  analog  scale  was  assessed
by  ANOVA  on  Ranks.  The  difference  of  epithelialized  areas
was  assessed  with  one-way  ANOVA  (Sigma  Stat  3.5,  Ger-
many).  Significance  was  defined  as  p  <  0.05.
Results
Fifteen  patients  requiring  skin  grafting  for  the management
of trauma  injuries  were  included  (Fig.  4). There were  11  men
and  4  women  with  a median  age of  27  years  (range  10--68)
(Table  1).
Postoperative  donor  site  pain  was  consistently  lower  in
the  areas  covered  with  Mepilex® during  the study.  The  mean
pain  scores  for  the  entire  treatment  period  were  6.07  ±  1.46
Table  1  Wound  etiology  and  patient  characteristics.
Etiology  n
Trauma  9
Burn  4
Tumor  resection  2
Gender
Male  11
Female 4
Age, yrs.  median  (range)  27  (10--68)
for  control  and  1.72  ±  1.6  for Mepilex®.  The  analysis  of  each
time  point showed  similar  results:  on  day three,  patients
reported  a mean  VAS  score  of  3.4  ±  1.3  for the Mepilex®
group  and 7.07  ±  1.16  for  the  control  group;  at day  five
1.87  ± 1.55  in the Mepilex® group  and  6.33  ±  1.4  in the
control  group;  at day seven  0.93  ±  1.03  in  the  Mepilex®
group  and  5.8  ±  1.21  in  the  control  group,  and  on  day nine
0.67  ± 0.82  in the  Mepilex® group  and  5.07  ±  1.39  in the
control  group (p  <  0.001)  (Fig.  5).  Further  analysis  revealed
similar  results  in  the  patients  with  unilateral  treatment
(both  for  Mepilex® and  Adaptic  on  the same  thigh)  and  those
treated  bilaterally  (Mepilex® on  one thigh  and  Adaptic  on  the
contralateral  one)  (p  <  0.001)  (Fig.  6a  and b).
Regarding  epithelialization,  there  was  no  significant  dif-
ference  between  both  groups  at  day  ten,  (99.55  ±  0.09%  in
the  Mepilex®-covered  areas  vs.  99.91  ±  0.18%  in the con-
trol  group;  p = 0.69).  At  day eight,  the  areas  covered  with
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Figure  4 Study  algorithm.
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Figure  5  General  Pain  Assessment.  Pain  scores  were  consis-
tently  lower  in  the  Mepilex  group  at all  times  during  the  study.
* p  <  0.001(see  text  for  details).  VAS:  visual  analog  scale.
Mepilex® were  only  95.94%  epithelialized,  a  finding  that
was  statistically  different  with  both  groups  on the 10th  day
(p  =  0.008  vs.  control  and  p = 0.008  vs.  Mepilex® at  day  ten)
(Fig.  7).  The  comparison  between  unilateral  and  bilateral
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Figure  6  Pain assessment  by  groups.  The  analysis  of  the
groups  showed  significantly  less  pain  in the areas  covered  with
Mepilex® at  all time  points  (p  <  0.01).  (a)  Bilateral  donor  sites.
(b) Unilateral  donor  sites.  VAS:  visual  analog  scale.
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Figure  7 General  epithelialization  assessment.  Areas  covered
with Mepilex  were  partially  epithelialized  at day  8 (95.94%,)
significantly  different  that  control  and  Mepilex  at  day  10
(p =  0.008).  At  day  10, no significant  difference  was  observed.
treatments  showed  practically  identical  results:  Mepilex®-
covered  areas  were 95.74%  epithelialized  at  day 8  in the
unilateral  group  vs. 99.38%  at  day  10  (p  =  0.003)  and vs.
99.92%  in the  control  group  (p  < 0.001)  (Fig.  8a).  In  the bilat-
eral  group,  the areas  covered  with  Mepilex® were  95.94%
healed  at day 8  vs.  99.55%  at  day  10  (p  = 0.008)  and  vs.
99.90%  in the control  group  (p  = 0.008)  (Fig.  8b).
Discussion
The  choice  of  the  dressing  for  the donor  site  can have a
major  impact on  patient  satisfaction  and  recovery.15 Skin-
graft  harvesting  results  in large  open  surface  areas  that
are  prone  to  pain,  infection  or  other  morbidities.16,17 Donor
site  management  plays  an important  and  critical  role  in the
evolution  and  rehabilitation  of  patients  because  early  reha-
bilitation  and mobilization  is  critical  for  achieving  optimal
outcomes  in burn  patients.18,19
Pain  impairs  prompt  rehabilitation,  since  pain  related
to  donor  sites  is  the most  important  complaint  within
the first  ten  days  after  graft  harvesting  in burn  patients.7
Therefore,  by  decreasing  pain,  we  could  potentially  help
the  early  mobilization  of patients,  especially  in  pediatric
populations.
All  kinds  of dressings  are  reported  in  the  literature  for
donor  site  management,  but  they  all  have different  draw-
backs  and the  ideal  dressing  has  yet  to  be described.20,21
In our  continuous  search  for  available  material  that  best
suits  the  needs  of our  burn  patients,  we  decided  to  assess
Mepilex® for  its  potential  advantage  of  pain  reduction
without  affecting  the epithelium.  The  principal  aim  of
our  study  was  to  assess  the  reduction  of  pain  of  donor
sites.  Since  pain  is a  subjective  parameter  and  varies  from
individual  to  individual,  it  is very  difficult  to  make  objec-
tive  and  reliable  measurements.22 Therefore,  we  used  the
VAS,  which  is  a  widely-used  and  accepted  tool  for pain
assessment.15,23
Donor  areas  were  located  in the  anterolateral  thigh  in all
cases  to  reduce  variability  of  pain  related  to  the topographic
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Figure  8  Epithelialization  assessment  by  groups.  The  areas
covered with  Mepilex  were  significantly  less  epithelialized  at
day 8  than  day  10  in  both  groups.  (A)  Bilateral  donor  sites.
(B) Unilateral  donor  sites  (see  text  for  details).  *  p  =  0.003  vs.
Mepilex  10  days. ¥ p  <  0.001  vs.  control
area.  We  decided  to  include  patients  with  unilateral  and
bilateral  donor  sites  to  compare  the  effect  of the dressing
in  reducing  pain  because  either  approach  has  its  pros  and
cons.  In  both  cases,  the patient  serves  as  his own  control,
which  is  desirable  since  using  different  patients  for  control
and  treatment  groups  makes  elimination  of the psychologi-
cal  effect  of  every  individual  on  the perception  of pain  very
difficult,  increasing  the  bias  of the study.  By  dividing  the
donor  sites  into  halves  (proximal  and  distal)  we are assessing
the  same  anatomic  area,  decreasing  variability  for  a differ-
ent  topographic  area. Even  though  there  is  a reasonable
possibility  for  poor  discrimination  of  pain  between  adja-
cent  zones,  the  scores  were  significantly  different  in  both
areas,  confirming  that  the  patient  is  capable  of  discriminat-
ing  the  pain  in two  adjacent  areas.  The  bilateral  treatment
allowed  removal  of  the theoretical  difficulty  of effectively
discriminating  pain  in two  adjacent  areas,  but  it includes
the  bias  of two  topographic  areas.  Nevertheless,  since  pain
was  effectively  reduced  with  Mepilex® in both  cases,  we  can
state  its  superiority  over  the  standard  management  in  pain
reduction.
We  usually  remove  the  non-adherent  gauze  of  donor  sites
at  day 10  because  we  have  found that  epithelialization  is
complete  by that time,  and previous  attempts  to remove
the  gauze  earlier  led  almost  invariably  to unhealed  wounds.
Therefore,  we  decided  to  remove  the dressings  on  that  day
and chose  it as  the final  time  point  for  comparison.
Since  epithelialization  was  practically  completed  in both
groups  by  day 10 and this was  not statistically  different
(p  =  0.29),  we  can  conclude  that  Mepilex® does  not  impair
epithelialization  of  donor  sites.  We  decided  to  remove
Mepilex® before  the 10th day  because  we  wanted  to  see  if it
would  improve  epithelialization.  It was  arbitrarily  decided
to  set  day 8 to  assess  epithelialization  in the  Mepilex® group,
because  if it actually  did  improve  epithelialization,  this
would  be clinically  relevant.  Since  epithelialization  was  sta-
tistically  and clinically-relevant  incomplete  by  day 8, we
do  not advise  removal  on  that  day.  A new  study  would  be
needed  to  assess  if Mepilex® can  induce  full  epithelialization
by  day  9, but  we  believe  that  this  is  unlikely  and  clinically
irrelevant.  An  exception  for  this  would  be in severely  burned
patients  who  typically  require  several  graft  takes  and  one
day saved  with  each  harvest  would  be advantageous.
Even  though  the  sample  size  is  relatively  small  (15
patients),  statistical  significance  and  power  was  achieved
(p  <  0.001,  power  1.00).  Therefore,  we  do  not  believe
that  increasing  the  sample  size  would influence  outcome.
Another  limitation  of  this  study  is  the fact that  the  patient
was  not blinded  to  the treatment  and  it  is  difficult  to  elimi-
nate  the placebo  effect.  It  was  not  possible  to  get dressing
material  without  Safetac  Technology.  Perhaps  future  studies
can  compare  other  occlusive  dressing  material  to  determine
if  this  type  of  technology  is  responsible  for  the  observed  pain
reduction  or  the occlusive  method  per  se.
However,  we  found  that  Mepilex® was an  easy-to-use
dressing,  painless  at removal,  and  maintained  its  position
during  the whole  treatment  period,  which  is  not always
possible  with  other  dressing  materials;  e.g.,  hydrocolloids.
Another  advantage  was  that  in this type of  moderately
exudating  wound,  Mepilex® efficiently  absorbed  exudates
without  the need  of  secondary  dressings.  It was  not nec-
essary  to  change  the patch  due  to  fluid  saturation  at  any
time.  The  fact  that there  was  no impairment  in the rate  of
epithelialization  in the covered  donor  site encourages  its use
in  cases  where the donor  area  is  required  to  be  in  contact
with  the bed; e.g.,  posterior  thigh  or  patients  in a prone
position.  It is  well  known  that  this  practice  may  complicate
these areas  with  conventional  management.  There  were  no
reports  of  adverse  effects  with  the use  of  Mepilex® in any
patient  and they  preferred  the  use  of  Mepilex® dressing
instead  of  standard  management  in all  cases.
Therefore,  we  can  conclude  that  the use  of Mepilex®
translates  into  a significant  and  relevant  reduction  of  pain
in  donor  sites  without  affecting  epithelialization.
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